摘要
目的观察重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白联合甲氨蝶呤（MTX）治疗中重度斑块型银屑病的临床疗效及安全性。方法选取2009年8月至2012年8月来我院皮肤科进行治疗的中重度银屑病患者90例，采用抽签随机法分为研究组和对照组各45例。对照组患者每周一次口服甲氨蝶呤10mg；研究组患者每周二次皮下注射重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白，每次25mg，每次间隔3～4天，同时口服甲氨蝶呤10mg，每周一次。结果两组治疗4、8、12周后的PASI50、PASI75和PASI90比较，差异均有统计学意义（P〈0．05）；两组均无严重不良反应。结论重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白联合甲氨蝶呤治疗中重度斑块型银屑病能够更好的控制病情，无严重不良反应。
Objective To evaluate the efficacy and safety of combined treatment with Recombinant Human Tumor Necrosis Factor-ctReceptor Ⅱ ： IgG-Fc fusion protein （ rhTNFR ： Fc） and methotrexate for moderate to severe plaque psoriasis. Methods Totally, 90 patients with moderate to severe plaque psoriasis treated in our hospital from August 2009 to August 2012 were enrolled in this re- search. They were allocated randomly into research group and control group,45 volunteers in each group equally. Patients in control group received 10 mg of methotrexate orally once a week. While patients in research group were administered with 25 mg of rhTNFR：Fc subcutaneously every 3 or 4 days,combined with 10 mg of methotrexate orally once a week. Results Significant differences were ob- served in PASI 50,PASI 75 and PASI 90 between these two groups during 4,8 and 12 weeks of treatment（P 〈 0. 05）. No serious ad- verse reactions were reported in either group. Conclusions Combined treatment with rhTNFR：Fc and methotrexate provides satisfacto- ry management for moderate to severe plaque psoriasis without any serious adverse reactions.
出处
《实用医院临床杂志》
2013年第5期133-135,共3页
Practical Journal of Clinical Medicine
